Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Capodanno

Showing results (61-70 of 778) with videos related to

Pageof 78
Sort By:
JACC. Asia|March 6, 2023
Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary InterventionAntonio Greco, Davide Capodanno
JACC. Cardiovascular Interventions|May 29, 2024
Rethinking Aspirin: Ditching the Daily "Pill"ar of TraditionSimone Finocchiaro, Davide Capodanno
Thrombosis and Haemostasis|April 25, 2025
Factor XI Inhibitors for Myocardial Infarction: A Safer Path to Thrombotic Protection?Marco Spagnolo, Davide Capodanno
Expert Review of Cardiovascular Therapy|March 9, 2013
Dual antiplatelet therapy in patients with diabetes mellitus: special considerationsPiera Capranzano, Davide Capodanno
JACC. Cardiovascular Interventions|October 7, 2023
Short Dual Antiplatelet Therapy in High Bleeding Risk Patients: 1 Month or 3 Months?Davide Capodanno, Antonio Greco
European Heart Journal Supplements : Journal of the European Society of Cardiology|June 13, 2024
Factor XI inhibition in patients with acute coronary syndromeCarmelo Raffo, Davide Capodanno
JACC. Cardiovascular Interventions|April 9, 2016
Radial Access Reduces Mortality in Patients With Acute Coronary Syndromes: Results From an Updated Trial Sequential Analysis of Randomized TrialsGiuseppe Andò, Davide Capodanno
Minerva Cardioangiologica|March 3, 2016
Long-term antithrombotic pharmacotherapy following ST-elevation myocardial infarctionSergio Buccheri, Davide Capodanno
Journal of Cardiovascular Medicine (Hagerstown, Md.)|November 27, 2014
Reply to the letter: 'the effects of CPAP in OSAS patients with coronary artery disease: still not completely understood'Davide Capodanno, Corrado Tamburino
Kardiologia Polska|January 17, 2024
SGLT2 inhibitors and the risk of contrast-induced acute kidney injury: Time for a PCI Trial?Davide Capodanno, Simone Finocchiaro
Pageof 78

Showing results (61-70 of 778) with videos related to

Sort By:
Pageof 78
JACC. Asia|March 6, 2023
Shortening Dual Antiplatelet Therapy Duration in High-Risk Patients Undergoing Percutaneous Coronary InterventionAntonio Greco, Davide Capodanno
JACC. Cardiovascular Interventions|May 29, 2024
Rethinking Aspirin: Ditching the Daily "Pill"ar of TraditionSimone Finocchiaro, Davide Capodanno
Thrombosis and Haemostasis|April 25, 2025
Factor XI Inhibitors for Myocardial Infarction: A Safer Path to Thrombotic Protection?Marco Spagnolo, Davide Capodanno
Expert Review of Cardiovascular Therapy|March 9, 2013
Dual antiplatelet therapy in patients with diabetes mellitus: special considerationsPiera Capranzano, Davide Capodanno
JACC. Cardiovascular Interventions|October 7, 2023
Short Dual Antiplatelet Therapy in High Bleeding Risk Patients: 1 Month or 3 Months?Davide Capodanno, Antonio Greco
European Heart Journal Supplements : Journal of the European Society of Cardiology|June 13, 2024
Factor XI inhibition in patients with acute coronary syndromeCarmelo Raffo, Davide Capodanno
JACC. Cardiovascular Interventions|April 9, 2016
Radial Access Reduces Mortality in Patients With Acute Coronary Syndromes: Results From an Updated Trial Sequential Analysis of Randomized TrialsGiuseppe Andò, Davide Capodanno
Minerva Cardioangiologica|March 3, 2016
Long-term antithrombotic pharmacotherapy following ST-elevation myocardial infarctionSergio Buccheri, Davide Capodanno
Journal of Cardiovascular Medicine (Hagerstown, Md.)|November 27, 2014
Reply to the letter: 'the effects of CPAP in OSAS patients with coronary artery disease: still not completely understood'Davide Capodanno, Corrado Tamburino
Kardiologia Polska|January 17, 2024
SGLT2 inhibitors and the risk of contrast-induced acute kidney injury: Time for a PCI Trial?Davide Capodanno, Simone Finocchiaro
Pageof 78